New research suggests that statins, a common medication for managing cardiovascular risk, may be linked to more severe menopause symptoms in postmenopausal women. The study, published on June 22, 2026, examined data from 1,184 postmenopausal women across nine Latin American countries.
Researchers compared women taking statins with those who were not, looking at menopausal symptoms, muscle loss risk, and cognitive function. The study found that women on statins were 56% more likely to report severe menopausal symptoms compared to those not taking the medication. This difference remained even after researchers adjusted for factors like age and body weight.
Statin users also showed a 65% higher risk for sarcopenia, the gradual loss of muscle mass and physical function that often accelerates after menopause. Muscle loss at this stage is already a concern due to declining estrogen levels, and it is linked to a higher risk of falls, fractures, and reduced quality of life.
Additionally, statin users reported more intense musculoskeletal symptoms, with 53.1% experiencing such issues compared to 33.9% of non-users. This finding points to a broader pattern of physical discomfort that may go unrecognized in women on statins.
On the cognitive side, statin users showed slightly lower scores on tests of delayed memory recall and visuospatial function. However, no overall link to mild cognitive impairment was found, so researchers described these as early signals worth monitoring rather than firm conclusions.
The researchers noted that statin-related effects may overlap with menopause symptoms, making it difficult to tell them apart. Symptoms women attribute to menopause and side effects from statins can look similar, and in some cases, they may be compounding each other. Untangling the two is an open area of research.
The study authors cautioned that this research is not a reason to stop taking statins. For many women, the cardiovascular benefits are well-established, and stopping medication without medical guidance can carry serious risks. What the study offers is a fuller picture of what statin therapy might mean for postmenopausal women, a group historically underrepresented in cardiovascular research.
The findings add to a growing body of evidence that midlife women may need more individualized care. Women on statins who notice changes in muscle strength, physical function, or more intense menopause symptoms than expected are encouraged to discuss these issues with their doctor. Possible questions include whether symptoms are consistent with statin use, whether screening for muscle loss is needed, if the current statin is the best option, and what steps can be taken to protect muscles while on the medication, such as resistance training and adequate protein intake.
